Silencing Wnt5a restored the growth ability of prostate tumour cells, indicating a potential therapeutic role of Wnt5a in preventing bone metastatic recurrence by inducing cancer cell dormancy [28]. This evidence concerns the gene WNT5A and prostate neoplasm.